September 2024, Vol 14, No 9
The only tried and true method to achieve and maintain a successful revenue cycle
is through the careful creation of a strong foundation alongside attention to the
entire cycle. Read More ›
By Colleen Hall
While the panel acknowledged there is a long way to go in terms of encouraging diverse patient populations to participate in clinical trials, they note that there is reason for hope. Before the draft guidance was even issued by the FDA in June, several industry sponsors had already partnered with health care professionals to boost clinical trial participation. Read More ›
In recognition of Prostate and Ovarian Cancer Awareness months, we have
compiled a list of clinical trials in these areas to discuss with your patients. Read More ›
Oncology Practice Management (OPM) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
Oncology Practice Management (OPM) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities. Read More ›
The affordability of medication remains a substantial obstacle to care for many patients with cancer. According to the NCI, the per-patient annualized average costs of cancer diagnosis and treatment were highest in the last year of life, at $109,727 for medical services and $4372 for oral prescription drugs. Read More ›
Officials with the FDA approved durvalumab (Imfinzi; AstraZeneca) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥4 cm and/or node positive) NSCLC and no known EGFR mutations or anaplastic lymphoma kinase rearrangements. Read More ›
On August 14, 2024, the FDA approved axatilimab-csfr (Niktimvo; Incyte Corporation), a colony-stimulating factor-1 receptor–blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least 2 prior lines of systemic therapy. Read More ›
Officials with the FDA approved lazertinib (Lazcluze; Janssen Biotech, Inc) in combination with amivantamab-vmjw (Rybrevant; Janssen Biotech, Inc) for the first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. Read More ›
On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (Tecelra; Adaptimmune, LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices. Read More ›